Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a diabetes pill stop AFib from returning after ablation?

NCT ID NCT06528262

First seen May 14, 2026 · Last updated May 24, 2026 · Updated 3 times

Summary

This study is testing whether a drug called Enavogliflozin, currently used for diabetes, can help prevent atrial fibrillation (an irregular heartbeat) from coming back after a catheter ablation procedure in people who also have heart failure. About 390 adults aged 19 to 85 will be randomly assigned to receive either the drug or a placebo for one year. The main goal is to see if the drug reduces the rate of AF recurrence between 3 months and 1 year after the procedure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Severance Hospital

    RECRUITING

    Seoul, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.